Characterization of adverse events to hydroxychloroquine, ivermectin, azithromycin and tocilizumab in patients hospitalized due to COVID-19 in a Peruvian Social Health Insurance hospital.
L Yesenia Rodríguez-TantaEnrique Cachay RojasFabián FiestasGuisela Alva LozadaPaola Fernández-RojasRaquel Delgado-EscalantePublished in: Revista peruana de medicina experimental y salud publica (2023)
We found AEs potentially associated with the use of HQ, AZI, TOB and IVM against COVID-19; cardiovascular events were the most frequent. Although AZI, HQ and IVM have known safety profiles, their use against COVID-19 could increase the occurrence of AE due to the risk factors inherent to this infection. Surveillance systems must be improved, especially those for TOB.
Keyphrases
- coronavirus disease
- cardiovascular events
- health insurance
- sars cov
- risk factors
- end stage renal disease
- healthcare
- coronary artery disease
- newly diagnosed
- ejection fraction
- public health
- rheumatoid arthritis
- cardiovascular disease
- chronic kidney disease
- respiratory syndrome coronavirus
- risk assessment
- peritoneal dialysis
- affordable care act
- prognostic factors
- type diabetes